6353-7

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 471/04, A61K 31/44 // (C07D 471/04, 221:00, 209:00) — A1

(11) International Publication Number: **WO 99/64421**

(43) International Publication Date: 16 December 1999 (16.12.99)

(21) International Application Number: PCT/US99/12886

(22) International Filing Date: 9 June 1999 (09.06.99)

(30) Priority Data:

60/088,737	10 June 1998 (10.06.98)	US
60/091,666	2 July 1998 (02.07.98)	US
60/109,413	20 November 1998 (20.11.98)	US
60/115,089	7 January 1999 (07.01.99)	US
Not furnished	1 June 1999 (01.06.99)	US
Not furnished	9 June 1999 (09.06.99)	US

(71) Applicants *(for all designated States except US)*: ARENA PHARMACEUTICALS, INC. [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121 (US). SSP CO., LTD. [JP/JP]; 12–4, 2–chome, Hama–cho, Nihonbashi, Chup–ku, Tokyo 103–8481 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: CHALMERS, Derek, T. [US/US]; 347 Longden Lane, Solana Beach, CA 92075 (US). SATO, Susumoto [JP/JP]; 6–15–5, Tamatsukuri, Narita, Chiba (JP). KODA, Tadayuki [JP/JP]; 1–2–51, Highigadai, Narita, Chiba (JP).

(74) Agents: MILLER, Suzanne, E. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ACETYLCHOLINE ENHANCERS

(57) Abstract

Disclosed herein are quinoline derivatives having dual mechanistic properties, referred to in this patent document as "acetylcholine enhancers", i.e., compounds which evidence acetylcholinesterase (AChE) inhibition activity, and 5–HT3 receptor antagonist activity. A particularly preferred compound is 2–[2–(1–benzylpiperizin–4–yl)ethyl]–2,3–dihydro–9–methoxy–1*H*–pyrrolo[3,4–*b*]quinolin–1–one hemifumarate, referred to herein as Compound A ("Cm.A").